RecruitingAdvanced Solid Tumor
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.
Sponsor: Robert Bok, MD, PhD
You may qualify if…
- ✓ 1. Presence of at least one target pelvic, abdominal, thoracic, neck or extremity lesion detected by standard staging scans that, in the judgment of study investigator, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:
- ✓ a. Target lesion must measure at least 1.0 cm in long axis diameter on Computerized tomography (CT) or magnetic resonance imaging (MRI).
- ✓ 2. The participant is able and willing to comply with study procedures and provide signed and dated informed consent.
- ✓ 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- ✓ 4. Adequate renal function defined as creatinine \< 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \>50 mL/min (by the Cockcroft Gault equation).
- ✓ 5. Participants age 18 and older.
- ✓ Part B only:
- ✓ 6. Planned treatment for disease with either standard of care regimen or an investigational agent.
You may not qualify if…
- ✕ 1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
- ✕ 2. Patients with contra- indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
- ✕ 3. Patients with a metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.
- ✕ 4. Patients with poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160mm Hg or diastolic blood pressure greater than 100mm Hg.
- ✕ Note: The addition of anti-hypertensives to control blood pressure is allowed.
- ✕ 5. Patients with congestive heart failure or New York Heart Association (NYHA) status \>= 2.
- ✕ 6. Patients who are pregnant or lactating.
- ✕ 7. A history of clinically significant EKG abnormalities or myocardial infarction (MI) within 6 months of study entry.
Where it's recruiting
California
San Francisco
Source: ClinicalTrials.gov · NCT05599048 · last updated 2026-05-27